BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical Corporation announced today that it has completed a $3.75 million first closing of its $7 million convertible note offering. This funding will support the completion of the first clinical trial, and commercialization of the company’s Seraph® Microbind® Affinity Blood Filter (Seraph).
Seraph® can remove an extremely broad range of viruses, bacteria, fungi and toxins from whole blood. No other therapy —drug or medical device— is designed to be as effective as Seraph in removing so many different pathogens and toxins from the blood of viremic and bacteremic patients.
Help employers find you! Check out all the jobs and post your resume.
Seraph® can remove an extremely broad range of viruses, bacteria, fungi and toxins from whole blood. No other therapy —drug or medical device— is designed to be as effective as Seraph in removing so many different pathogens and toxins from the blood of viremic and bacteremic patients.
Help employers find you! Check out all the jobs and post your resume.
